Tilray Medical Launches Redecan Cannabis Brand in Australia

EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) — Tilray Medical, a division of Tilray Brands, Inc. (“Tilray Brands”) (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, strengthening the therapeutic alliance between patients and healthcare providers to make informed, individualized health decisions, today announced the launch of Redecan EU-GMP certified medical cannabis products in Australia.

Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, said: “The launch of Redecan, a premium cannabis brand, in Australia is another significant milestone for Tilray Medical as we relentlessly pursue our vision of making high-quality medicinal cannabis products accessible to patients globally. The launch of Redecan further expands our medicinal cannabis portfolios beyond our current Tilray and Broken Coast offerings as we continue our mission to empower patients and healthcare providers to find optimal therapeutic solutions.”

Jonathan Trodden, Managing Director of Tilray Medical Australia, added: “We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of high-quality medicinal cannabis to choose from.”

The following Redecan products are now available to medicinal cannabis patients in Australia:

Redecan PC THC28 Purple Churro – 15g
Redecan SA THC28 Space Age Cake – 15g

Tilray continues to be one of the leading providers of EU-GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments and researchers worldwide, and today offers a comprehensive portfolio of THC and CBD products in over 20 countries. In furtherance of its mission, Tilray has supported medical trials globally investigating the efficacy of medical cannabis as a treatment for indications including fibromyalgia, pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.

About Tilray Medical
Tilray Medical is committed to transforming lives and advancing dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved, licensed producer of medical cannabis in Canada to building the first EU-GMP certified cannabis production facilities in Europe, concurrently in Portugal and Germany. Today, Tilray Medical is one of the largest providers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments in 20 countries and across five continents.

For more information about Tilray Medical, please visit Tilray Medical Europe, Tilray Medical Canada and Tilray Medical Australia-New Zealand.

About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer products company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the intersection of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create unforgettable experiences. Tilray’s unparalleled platform supports more than 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

To learn more about how we improve lives through moments of connection, visit Tilray.com and follow @Tilray across all social platforms.

Forward-looking statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) within the meaning of Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements may be identified by words such as “predict”, “future”, “could”, “may”, “enable”, “potential”, “consider”, “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, targets, projections or assumptions were used in reaching the conclusions contained in the forward-looking statements in this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyses or current expectations. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties not currently known to the Company or that the Company believes to be immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained in this document. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed Annual Information Form and Tilray’s Annual Report on Form 10-K (and other periodic reports filed with the SEC) which is filed with the SEC and available on EDGAR. The forward-looking statements contained in this communication are made as of the date of this communication and the Company undertakes no obligation to publicly update any such forward-looking statements to reflect new information, subsequent events or otherwise, except as required by applicable securities laws.

For further information please contact:
Media: [email protected]
Investors: [email protected]